Skip to main content
Message from the Associate Chief for Translational Research

Dr. Anna Beaudin



Welcome to Research in the Division of Hematology and Hematologic Malignancies.  Our research mission is to capitalize on the rich legacy of hematology research founded by Dr. Max Wintrobe to continue growing an internationally-recognized hematology research program that supports and bridges both malignant and non-malignant research and integrates basic discovery research with clinical divisions. We capitalize on robust internal and external mentoring programs, strong support for translational pipelines, and a vibrant collegial and collaborative environment at the University of Utah. We also partner with several initiatives on campus, including the NIDDK-sponsored Cooperative Center for Excellence in Hematology, the Cell Therapy and Regenerative Medicine Program, and the Utah Stem Cell and Regenerative Medicine Initiative.  We aim to engage passionate, diverse translational researchers in a dynamic and growing hematology field, with an emphasis on hematopoietic stem cell biology, regenerative medicine, inflammation, and epigenomic regulation. 

Hematology Research

Research is an integral part of the Division of Hematology at the University of Utah with the robust research programs of past division chiefs, including Maxwell Wintrobe, George Cartwright, Jack Athens, and James Kushner laying this foundation of excellence. Physicians and basic scientists participate in a broad range of multidisciplinary research into malignant and non-malignant hematological disorders with the goals of understanding the basic biology of these disorders and developing therapeutics for improved clinical care of patients. Thus, basic, and translational research programs exist within the division.


Basic Research

Basic research is focused on:

  • Mechanisms of drug resistant BCR-ABL tyrosine kinases
  • Dysregulated iron metabolism (systemic disease, porphyrias and hemochromatosis)
  • Inflammation and immunologic cross-talk in hematopoiesis and carcinogenesis
  • Genomic variants regulating platelet function
  • Transcriptomic regulation of megakaryocytopoiesis
  • Molecular basis of polycythemias, defective erythropoiesis and other MPNs
  • Strategies to overcome resistance to CLL and lymphoma therapy
  • Immune mechanisms and novel therapies for graft versus host disease
  • Hematopoietic stem cell differentiation
  • Non-coding RNA research
  • Stem cell biology

Clinical & Translational Research Programs

Clinical and Translational research programs include:

  • Therapeutics for porphyrias
  • Novel therapeutics of hematologic malignancies including chronic myeloid leukemia, acute myeloid leukemia, myeloproliferative neoplasms and lymphoid malignancies
  • Understanding the biology of disease persistence in drug-resistant chronic myeloid and lymphoid leukemias
  • Understanding the mechanism of Factor VIII inhibitors in hemophilia
  • Lowering treatment costs in hemophilia
  • Development of novel cellular therapies for hematological malignancies
  • Genetic epidemiology of hematological malignancies
  • Outcomes research using national VA database, exploring novel methodologies
  • Regenerative medicine
  • Amyloidosis center of Excellence
  • Mastocytosis program


Important program: NIH-funded Center for Iron and Heme Disorders (U54, PI: John Phillips, PhD); this U54 supports several institutional-wide Core facilities

Faculty from our division were awarded $14,000,000 in extramural grant income in FY22; this is one indicator of the successful research programs within the division.

Good success with getting NIH K grants and other training awards for junior faculty


Help Progress, Give Today

You can help the Division of Hematology continue to progress with even a small contribution. Give today!